What is HC Wainwright’s Forecast for TLSI FY2026 Earnings?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Research analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of TriSalus Life Sciences in a research note issued to investors on Wednesday, November 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.62) for the year, down from their prior forecast of ($0.53). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for TriSalus Life Sciences’ Q4 2026 earnings at ($0.13) EPS, Q1 2027 earnings at ($0.16) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.10) EPS and FY2027 earnings at ($0.55) EPS.

A number of other research analysts have also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Wednesday, November 4th. Zacks Research upgraded shares of TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th. Canaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday. Citigroup restated a “buy” rating on shares of TriSalus Life Sciences in a research report on Tuesday. Finally, Stifel Nicolaus set a $12.00 price objective on shares of TriSalus Life Sciences in a research report on Wednesday, September 23rd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, TriSalus Life Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.20.

TriSalus Life Sciences Trading Up 9.6%

Shares of TLSI stock opened at $2.52 on Friday. The stock’s fifty day moving average is $4.10 and its 200-day moving average is $4.31. The company has a debt-to-equity ratio of 47.60, a quick ratio of 4.97 and a current ratio of 4.22. TriSalus Life Sciences has a 52 week low of $2.20 and a 52 week high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $12.88 million during the quarter, compared to analysts’ expectations of $14.02 million.

Institutional Trading of TriSalus Life Sciences

Hedge funds have recently modified their holdings of the company. First Light Asset Management LLC bought a new position in TriSalus Life Sciences during the 1st quarter worth approximately $20,267,000. BlackRock Inc. bought a new stake in TriSalus Life Sciences in the second quarter valued at approximately $12,099,000. Nantahala Capital Management LLC acquired a new stake in TriSalus Life Sciences in the second quarter worth $4,550,000. White Pine Capital LLC acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $2,143,000. Finally, State Street Corp grew its holdings in shares of TriSalus Life Sciences by 86.3% in the 2nd quarter. State Street Corp now owns 610,963 shares of the company’s stock valued at $2,780,000 after buying an additional 282,943 shares during the period. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.